natgillin/translations-raw huggingface dataset:
in free form or in salt form, and, where possible, in acid addition salt form. A pharmaceutical composition comprising a compound of claim 3, in free or salt form and, where possible, in pharmaceutically acceptable acid addition salt form, in association with a pharmaceutical carrier or diluent. 
Farmaceutski sastav, naznačen time, da on sadrži spoj prema zahtjevu 3, u slobodnom obliku ili u obliku soli, i, gdje je to moguće, u obliku farmaceutski prihvatljive kiselinske adicijske soli, zajedno s farmaceutskim nosačem ili sredstvom za razrjeđivanje.
The combination for use according to claim 16 containing dimethylfumarate at a dose range of 60 mg to 250 mg and teriflunomide at a dose range of 0.5 mg to 3 mg or fingolimod at a dose range of 0.025 mg to 0.20 mg. 
Kombinacija za uporabu prema zahtjevu 16. naznačena time što sadrži dimetilfumarat u rasponu doze od 60 mg do 250 mg i teriflunomid u rasponu doze od 0,5 mg do 3 mg ili fingolimod u rasponu doze od 0,025 mg do 0,20 mg.
The compound of claim 8 for use as a medicament, wherein the compound exists in polymorphic form having an XRPD diffraction pattern as indicated in Figure 18. 
Tvar iz patentnog zahtjeva 13, pri čemu tvar postoji u polimorfnom obliku i ima XRPD uzorak difrakcije kako je prikazano na Slici 18.
In addition to that venlafaxine hydrochloride is polymorphic. 
Uz to, venlafaksin-hidroklorid je polimorfan.
Accordingly, in a further aspect the invention relates to a compound of the invention as the free base or a salt thereof for use as a medicament, i.e. in particular a compound represented by the general formula I, IA, IB, IC, IE or IF, e.g. formula IA, wherein 
Prema tomu, u jednom daljnjem aspektu izum se odnosi na spoj izuma kao slobodne baze ili njezine soli za korištenje u obliku lijeka, npr. pogotovo kao spoj opće formule I, IA, IB, IC ili IF npr., formule IA u kojoj
The TNF family ligand trimer-containing antigen-binding molecule of claim 2, wherein the Fc domain is an IgG1 Fc domain or an IgG4 Fc domain. A tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecule comprising 
Molekula koja veže antigen i sadrži trimer TNF ligand obitelji prema bilo kojem od patentnih zahtjeva 1 do 10, naznačena time, da je Fc domena jedna IgG, prvenstveno IgG1 Fc domena ili IgG4 Fc domena.
Finally, 16 g of magnesium stearate were added and the mixing was continued for 3 minutes. 
Nakon toga je dodano 16 g magnezijevog stearata i miješanje je nastavljeno tijekom 3 minute.
wherein at least 50% of the active agent particle material by volume exhibits an optical diameter of 5 µm or less; and one or more species of respirable suspending particles; 
Farmaceutski pripravak u skladu s patentnim zahtjevom 2, naznačen time što najmanje 50% čestica glikopirolata kao aktivnog sredstva po volumenu pokazuje optički promjer od 5 µm ili manji.
Assay is stopped by spinning plates sealed with plate covers at 2500 rpm for 20 minutes at 22° C. 
Ispitivanje se zaustavlja spinom ploča zatvorenih sa poklopcem ploče pri 2500 okr./min. tijekom 20 minuta na 22C.
The compound of claim 1 having formula (III) or (IIIa) or a pharmaceutically acceptable salt thereof, wherein: 
Spoj u skladu s patentnim zahtjevom 1 formule (III) ili (IIIa)
51 . Even more surprising, however, the efficacy achieved by a lower dosage strength 3.75% imiquimod formulation when used in either a two-week or three-week 2-cycle treatment regimen of the present invention for treatment of actinic keratosis as for partial clearance of AK lesions is statistically significant over a lower dosage strength 2.5% imiquimod formulation when used in either a two-week or three-week 2-cycle treatment regimen. 
Farmaceutska formulacija, naznačena time što sadrži imikvimod u količini, težinski, od 2,5 % ili 3,75 %, namijenjena upotrebi u liječenju aktinične keratoze, koja se sastoji u primjeni formulacije imikvimoda na liječeno područje jednom dnevno, svaki dan, u ukupnom periodu liječenja do 4 tjedna, uključujući međuperiod mirovanja do 2 tjedna kako bi se postiglo u najmanju ruku djelomično uklanjanje AK lezija.
A further aspect of the present invention is directed to a pharmaceutical suspension formulation comprising about 0.003-0.04% formoterol fumarate dihydrate, about 0.01-0.06% fluticasone propionate, about 0.01-0.1% suspension agent and about 0.01-3% dehydrated alcohol. 
Farmaceutska suspenzijska formulacija, naznačena time što sadrži: a) 0,003-0,04%, težinski, formoterol-fumarata dihidrata; b) 0,01-0,6%, težinski, flutikazon-propionata;
Similarly, said net (230) on the other hand comprises at least one fastener (231). 
- najmanje jednom mrežom (230) kroz koju se propušta zrak apsorbiran putem hladnjaka(100),
Thus it is possible to match the force needed to operate the jar to the strength of the wireline being used and/or the mass of the toolstring, before the toolstring is inserted into the wellbore. 
To znači da je moguće pratiti silu potrebnu za rad udaraca u odnosu na jačinu žičane veze koja se koristi i/ili masu alata, prije nego što se alat unese u bušotinu.
The process of claim 39, wherein M1 is Li and R3 is Cl. 
Postupak prema patentnom zahtjevu 39, gdje je M' jednako Li i R? je CI.
upon detecting a dangerous leakage current disconnects the load from the mains and calls for a manual intervention of the user to re-establish the power supply. 
- >< nakon otkrivanja opasne parazitne struje, odspaja trošilo od izvoda i potrebno je da korisnik ručno ponovno uspostavi napajanje.
RY9A2v11(M34L)012 antibody The VH of RY9A2v11(M34L)012 antibody has the amino acid sequence shown by SEQ ID NO: 26, and VL has the amino acid sequence shown by SEQ ID NO: 63. 
(b) varijabilno područje jakog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NOQ:13 i varijabilno područje slabog lanca koje se sastoji od aminokiselinske sekvence prikazane sa SEQ ID NO:17;
The crude product was purified with a by chromatography on silica gel eluting with 50% ethyl acetate in hexane to yield the desired product compound 10c as a pale yellow solid (15 g, 24 mmol, 53%). 
Sirovi produkt pročisti se s kromatografijom na silikagelu, uz HR P20080646 T3 eluiranje 50 %-tnim etil-acetatom u heksanu kako bi se dobilo željeni produkt spoj 10c u obliku blijedožute krutine (15 g, 24 mmol, 53 %).
A process of producing glatiramer acetate comprising the steps of: polymerizing N-carboxyanhydrides of tyrosine, alanine, Y-benzyl glutamate and N-trifluoroacetyl lysine to form protected glatiramer acetate; deprotecting protected glatiramer acetate with a solution of hydrobromic acid in acetic acid, the solution comprises less than 0.5% of free bromine and less than 1000 ppm of metal ion impurities, to form trifluoroacetyl glatiramer acetate; 
Postupak za dobivanje farmaceutskog sastava koji sadrži glatiramer acetat, naznačen time, da sadrži a) polimeriziranje N- karboksianhidrida od tirozina, alanina, y-benzil glutamata i trifluoracetil lizina da bi se formirao zaštićeni glatiramer acetat; b) skidanje zaštite sa zaštićenog glatiramer acetata otopinom bromovodične kiseline u octenoj kiselini, koja je otopina prethodno obrađena hvatačem broma radi uklanjanja slobodnog broma, da bi se formirao trifluoracetil glatiramer acetat;
*The fuel rod in this model was not wrapped with cigarette paper. 
* Gorivi štap u ovom proizvodu nije bio omotan sa cigaret papirom.
and pharmaceutically acceptable salts thereof. A compound according to claim 1 wherein R3 represents a phenyl group optionally substituted by one, two or three halogen atoms or by a C1-C6 alkoxy group optionally substituted by one, two or three halogen atoms. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što R3 predstavlja fenilnu skupinu koja može biti supstituirana s jednim, dva ili tri atoma halogena ili sa skupinom C1-C6 alkoksi koja može biti supstituirana s jednim, dva ili tri atoma halogena.
said AlOOH/HBsAg complex is mixed with the Hib antigen in the presence of cationic amino acids at a concentration of at least 100 mg/l and of phosphate ions at a concentration of 35 to 45 mMol/l. 
- navedeni AIOOH/HBsAg kompleks se miješa s Hib antigenom u prisutnosti kationskih aminokiselina u koncentraciji od barem 100 mg/l i fosfatnih iona u koncentraciji od 35 do 45 mMol/l.
with morpholine in an organic solvent. 
S prikladnom kiselinom u prikladnom otapalu.
The method according to claim 3, wherein the LBAS GT converts information of a specific geographical area to cell ids, by reading a database list with information on which area each cell is covering, and screening only cells that are located in the relevant geographical area before the information is sent to the A-SMSC. 
Postupak prema zahtjevu 3, naznačen time da LBAS GT (40) pretvara informacije za određeno zemljopisno područje u brojeve stanica, čitanjem popisa iz baze podataka s informacijama koje područje pokriva svaka stanica, te se vrši probiranje samo onih stanica koje se nalaze u određenom zemljopisnom području prije nego se navedene informacije šalju prema A-SMSC (30).
A heat transport system arranged to maintain a set point temperature or set point temperature range of a chamber or surface of a refrigeration system, the heat transport system comprising: 
Sustav prijenosa topline (200; 250) uređen za održavanje potrebne temperaturne vrijednosti ili potrebnog raspona temperaturne vrijednosti za komoru ili za površinu, pri čemu taj sustav prijenosa topline obuhvaća sljedeće:
In one aspect, the disclosure provides a method for enhancing expression of recombinant protein in cell culture comprising culturing cells that express the recombinant protein in culture media comprising an amount of alkyl-amine-n-oxide (AANOx) sufficient to improve the growth rate of the cells in culture. 
Postupak poboljšavanja eksprimiranja rekombinantnog čimbenika zgrušavanja krvi u kulturi stanica koja sadrži uzgajane stanice koje eksprimiraju rekombinantni čimbenik zgrušavanja krvi u mediju za uzgoj u kulturi koja sadrži količinu alkil-amin-N-oksida (AANOx) dovoljna za poboljšavanje stope rasta stanica u kulturi, naznačen time što se količina AANOx kreće između 4 i 80 ppb, te
The sole for shoes according to claim 1, wherein said protective elements include flat vapor-permeable or microperforated elements, which include microstretched metal sheets, fused and partially compressed synthetic fibers, and compressed natural fibers. 
Potplat za cipele u skladu s bilo kojim patentnim zahtjevom 2 do 7, naznačen time, da su navedeni zaštitni elementi (18, 118) sačinjeni od ravnih paropropusnih ili mikroperforiranih elemenata, koji su sačinjeni od mikronategnutih metalnih pločica, rastaljenih i djelomično stlačenih sintetskih vlakana te stlačenih prirodnih vlakana.
A pharmaceutical composition as defined in any one of claims 1 to 28 for use in the treatment of a pulmonary disease or disorder. 
Farmaceutski pripravak kako je definirano u bilo kojem od zahtjeva 1 do 20 naznačen time što se koristi u postupku liječenja plućne bolesti ili poremećaja kod pacijenta.
Method according to claim 1, wherein timestamps are used for the first and second transaction identifiers, wherein the first transaction identifier is related to a first point in time, wherein the second transaction identifier is related to a second point in time, wherein the first point in time is related to the first transaction step (21), wherein the second point in time is related to the second transaction step (22). 
2. > Metoda u skladu s patentnim zahtjevom 1, naznačena time što se vremenske oznake koriste za prvi i drugi pokazatelj prijenosa, pri čemu je prvi pokazatelj prijenosa, povezan s prvom točkom u vremenu, pri čemu je drugi pokazatelj prijenosa povezan s drugom točkom u vremenu, pri čemu se prva točka u vremenu odnosi na prvi korak prijenosa (21), pri čemu je druga točka u vremenu povezana s drugim korakom prijenosa (22).
M comprises a humanized anti-DLL3 antibody comprising a light chain variable region set forth as SEQ ID NO: 212 and a heavy chain variable region set forth as SEQ ID NO: 213; L comprises a linker; 
Konjugat protutijelo-lijek prema bilo kojem od zahtjeva 1 do 5, naznačen time, da protutijelo anti-DLL3 obuhvaća varijabilno područje slabog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:212 1 varijabilno područje jakog lanca koje obuhvaća aminokiselinsku sekvencu prema SEQ ID NO:213.
A method of claim 9, wherein the disease state is selected from a group consisting of: chronic obstructive pulmonary disease, anaphylactic shock fibrosis, psoriasis, allergic diseases, asthma, stroke, ischemia-reperfusion, platelets aggregation/activation, skeletal muscle atrophy/hypertrophy, leukocyte recruitment in cancer tissue, antiogenesis, invasion metastasis, melanoma, Karposi's sarcoma, acute and chronic bacterial and virual infections, sepsis, transplantation rejection, graft rejection, glomerulo sclerosis, glomerulo nephritis, progressive renal fibrosis, endothelial and epithelial injuries in the lung, and lung airways inflammation. 
Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 5, naznačen time što se bolesno stanje bira iz skupine koju čine: kronična opstruktivna plućna bolest, anafilaktički šok, fibroza, psorijaza, alergijske bolesti, astma, inzult, ishemija-reperfuzija, agregacija/aktivacija trombocita, atrofija/hipertrofija skeletnih mišića, novačenje leukocita u tkivu raka, antiogeneza, invazivna metastaza, melanom, Kaposijev sarkom, akutne i kronične bakterijske i virusne infekcije, sepsa, odbacivanje transplantacije, odbacivanje presatka, glomeruloskleroza, glomerulonefritis, progresivna fibroza bubrega, ozljede endotela i epitela u plućima, te upala dišnih putova pluća.
coating said tablets to a first weight gain; 
- > prenošenje navedenih tableta u posudu za oblaganje;
Method for odorising a packaging according to claim 9, wherein said oiler or nebuliser (30) is of the type comprising a Venturi tube for drawing the odorising/aromatising liquid (L) and mixing it with the gas mixture (G1+G2) produced and fed by the mixing system (20). 
Metoda za odorizaciju pakiranja prema patentnom zahtjevu 9, gdje je rečeno uljilo ili atomizer (30) tip koji sadrži Venturijevu cijev za povlačenje odorizirajuće/aromatizirajuće tekućine (L) i njeno miješanje sa smjesom plinova (G1+Q2) koju proizvodi i opskrbljuje sustav miješanja (20).
The human ssAAV vector for use according to any one of claims 1 to 7, wherein the AAV vector comprises a replication defective AAV genome lacking functional Rep and Cap coding viral sequences. 
AAV vektor iz bilo kojeg od patentnih zahtjeva 1 do 5, pri čemu AAV vektor obuhvaća replikacijom nedostatan AAV genom bez funkcionalnih Rep i Cap kodirajućih virusnih sljedova.
The liquid, unit-dose pharmaceutical composition of claim 11, wherein said single unit-dose container comprises high density polyethylene. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačen time što navedeni spremnik za jednu jediničnu dozu sadrži polietilen visoke gustoće.
effecting the hydrolysis of a compound of formula (IIa): 
(a) hidrolizu spoja formule (II):
The method of claim 17, wherein the human retinal pigmented epithelial cells are ARPE-19 cells deposited with the American Type Culture Collection (ATCC) as Accession No. 
Postupak prema patentnom zahtjevu 17, naznačen time što humane retinalne pigmentisane epitelne stanice su ARPE-19 ćelije deponovane u American Type Culture Collection (ATCC) kao pristupni br.
The residue was purified by flash chromatography (SiO2) using 30% ethyl acetate-hexanes to give the desired product (0.95 g) as a yellow solid. 
Ostatak se pročisti svjetlosnom kromatografijom (SiO02) uporabom 30% etil acetat-heksana da bi se dobio željeni produkt (0.95 g) kao žuta krutina.
8% or more, will stabilise the tetragonal phase and the cubic phase to such an extent that the activation barrier will become too high to overcome with most trigger process. 
8% ili više, stabilizirat će tetragosnku fazu i kubičnu fazu do te mjere da će aktivacijska barijera postati previsoka da se prevlada s većinom postupaka za poticanje.
A pharmaceutical composition comprising the salt of claim 1, and one or more pharmaceutically acceptable excipients. 
Farmaceutski sastav, naznačen time, da obuhvaća sol iz zahtjeva 1 ijedno ili više farmaceutski prihvatljivih pomoćnih sredstava.
The composition of claim 8 or 9, wherein the amount per unit dose is based on the content of quetiapine in the compound, salt thereof, or their combination. 
Pripravak sukladno zahtjevu 6 ili 7, naznačeno time, da je količina po pojedinačnoj dozi bazirana na sadržaju kvetiapina u konjugatu, njegovoj soli ili njihovoj kombinaciji.
The pharmaceutical composition of claim 1, wherein the nanoparticles are formulated for administration to a subject having a disease wherein suppression of a specific immune response is beneficial. A method of treating a disease wherein suppression of a specific immune response is beneficial, comprising administering the pharmaceutical composition of claim 1, wherein said disease is selected from the group consisting of multiple sclerosis type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, degeneration after trauma or stroke, graft versus host disease, transplant rejection, inflammatory bowel disease (IBD), asthma and allergy. 
Farmaceutski sastav za uporabu u proizvodnji regulacijskih T-stanica specifičnih za najmanje jedan epitop T-stanice kod pojedinca, u liječenju ili prevenciji bolesti kod koje je obuzdavanje specifične imunološke reakcije blagotvorno, prema bilo kojem od prethodnih zahtjeva, naznačen time, da je navedena bolest odabrana iz skupine koja se sastoji od autoimune bolesti, alergije ili bolesti kod koje je upalni process neumjeren, kroničan ili štetan.
In this publication a container containing carbonated drink, in particular beer, is described, wherein the beer is packed in a flexible bag, which bag is accommodated in a rigid plastic container. 
U ovom izdanju opisan je spremnik koji sadrži gazirano piće, napose pivo, pri čemu se pivo nalazi u fleksibilnoj vreći, koja je smještena u krutom plastičnom spremniku.
The advantageous pharmacokinetic profile of the compounds of the invention is readily demonstrated using conventional procedures for measuring the pharmacokinetic properties of biologically active compounds. 
Povoljni farmakokinetički profil spojeva prema ovom izumu lako se dokazuje konvencionalnim postupcima mjerenja farmakokinetičkih svojstava biološki aktivnih spojeva.
The method according to claim 1, wherein the surface-treated calcium carbonate is in powder form and/or in the form of granules or in the form of slurry. The method according to claim 1, wherein the surface-treated calcium carbonate is incorporated in a nonwoven fabric. 
Površinski obrađeni kalcijev karbonat prema bilo kojem od zahtjeva 1 do 10, naznačen time da je površinski obrađeni kalcijev karbonat u praškastom obliku i/ili u obliku granula ili u obliku guste otopine.
A ruminant milk fat for food application of said milk fat, which has a saturated fatty acid content less than 50% by weight based on the total fatty acids. 
Mliječna mast preživača za prehrambenu primjenu spomenute mliječne masti, naznačena time da je udio zasićene masne kiseline manji od 50% po težini na temelju ukupnih masnih kiselina.
wherein the pharmacokinetic parameter tmax, expressed as a mean value, is within the range of from 0.5 to 16 h, for use in the treatment of nociceptive pain, wherein the pharmaceutical dosage form is administered orally once daily. 
pri čemu je farmakokinetički parametar tax, izražen kao srednja vrijednost u rasponu od 0,5 do 16 h, naznačen time što je za uporabu za liječenje nociceptivne boli, pri čemu se farmaceutski oblik doziranja primjenjuje oralno jednom dnevno.
may additionally be hydrogen, cyano, C1-C6alkyl or C1-C6alkoxycarbonyl, or R5 and R6 together with the carbon atom to which they are bonded form a 3- to 10-membered ring which is optionally substituted by one to four substituents independently selected from C1-C6alkyl, C2-C6alkenyl, C1-C6alkoxycarbonyl, halogen, nitro, or phenylcarbonyl, or 
može dodatno biti vodik, cijano, C1-C6alkil ili C1-C6alkoksikarbonil, ili i R6 zajedno s atomom ugljika na koji su povezani tvore 3- do 10-člani prsten koji je opcijski supstituiran jednim do četiri supstituenata neovisno odabranim od sljedećih:
Process according to claim 1, characterized in that the optically active pirlindole enantiomers are enantiomerically pure (S)-pirlindole or (R)-pirlindole. 
Proces u skladu sa patentnim zahtjevom 1, naznačen time da optički aktivni enantiomeri pirlindola su enantiomerno čist (S)-pirlindol ili (R)-pirlindol.
reacting a compound of formula (A) with a compound of formula (B) in the presence of a palladium catalyst to form a compound of formula (XX) and 
ili njegove farmaceutski prihvatljive soli, koji sadrži korake: reakcije spoja formule sa spojem formule da bi se formirao spoj koji ima formulu:
a ring of cord at least partially wound around the pulley, having two cord sections moving away from the pulley in the same direction, in diametrically opposite positions with respect to the pulley, a tension applied to one of said cord sections generating a torque tending to rotate the pulley; means for transmitting said torque from the pulley to said movement group so as to cause said movement; 
* prsten užeta (8), u najmanju ruku djelomično namotan oko kolotura, gdje se dva dijela užeta (8a, 8b) odmiču od kolotura u istom smjeru, u dijametralno suprotnim položajima u odnosu na kolotur, gdje napinjanje jednog od navedenih dijelova užeta (&a, 8b) stvara moment koji zakrene kolotur;
The retentate fraction was collected and the ultrafilter washed with purifed water. 
Zaostala frakcija sakupljena je, a ultrafilter je opran s pročišćenom vodom.
It is advantageous to have a suncare formulation that is waterproof. 
Korisno je imati pripravak za zaštitu od sunca koji je vodootporan.
wherein the first vertically oriented corrugated plate of the upper portion and the second vertically oriented corrugated plate of the upper portion are positioned in antiphase to the first vertically oriented corrugated plate of the lower portion and the second vertically oriented corrugated plate of the lower portion. 
Kompenzacijski spoj prema bilo kojem od zahtjeva 3 do 9, naznačen time da gornji dio (2) nadalje sadrži drugi razdjelni element, kao što je druga okomito orijentirana valovita ploča (6), koja se uklapa unutar nabora (11) okomito orijentirane valovite ploče (4) gornjeg dijela.
The mouse of Clause 19, wherein the mouse portion of the chimeric MHC I polypeptide is derived from H-2K. The mouse of Clause 18, wherein the second nucleotide sequence encodes a chimeric human/mouse MHC II a polypeptide, the third nucleotide sequence encodes a chimeric human/mouse MHC II B polypeptide, and mouse portions of the chimeric MHC II a and B polypeptides are derived from H-2E or H-2A. 
Miš prema zahtjevu 8, naznačena time, da druga nukleotidna sekvenca kodira kimerni ljudski/mišji MHC-II-a- polipeptid, treća nukleotidna sekvenca kodira kimermi ljudski/mišji MHC-II-B-polipeptid, i pritom se mišji dio kimernog MHC-II-a-polipeptida kodira putem mišjeg gena razreda I odabranog iz skupine koja se sastoji od bilo kojeg gena a-lanca od H-2E i H-2A, dok se mišji dio kimernog MHC-II-B-polipeptida kodira putem mišjeg gena razreda II odabranog iz skupine koja se sastoji od bilo kojeg gena fB-lanca od H-2E i H-2A.
A method of scavenging hydrogen sulfide as claimed in claim 6, wherein said hydrocarbon includes crude oil, fuel oil, sour gas, and asphalts and refined products contained in storage tanks, vessels, and pipelines. 
Metoda čišćenja vodik sulfida temeljem bilo kojeg od zahtjeva 7 do 10, pri čemu navedeni ugljikovodik uključuje sirovu naftu, ulje za loženje, sumporovodik i asfalte i rafinirane proizvode sadržanima u tankovima za skladištenje, spremnicima, cjevovodima.